Advanced glycation index and its association with severity of diabetic retinopathy in type 2 diabetic subjects

Journal of Diabetes and its Complications

Volumn 22, Issue 4, 2008, Pages 261-266

  Anitha, Balaji ^a   Sampathkumar, Rangasamy ^a   Balasubramanyam, Muthuswamy ^a   Rema, Mohan ^a  

^a MADRAS DIABETES RESEARCH FOUNDATION   (India)

Author keywords

AGE; AGI; Diabetic retinopathy; Type 2 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SPECTROFLUOROMETRY; STATISTICAL ANALYSIS;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INDIA; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 45849094052     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2007.05.005     Document Type: Article

References (33)

1. Bacala R., and Vlassara H. Advanced glycation endproducts in diabetic renal and vascular disease. American Journal of Kidney Diseases 26 (1995) 875-888
2. Balasubramanyam M., Rema M., and Premanand C. Biochemical and molecular mechanisms of diabetic retinopathy. Current Science 83 (2002) 1506-1514
3. Boehm B.O., Schilling S., Rosinger S., Lang G.E., Lang G.K., Kientsch-Engel R., et al. Elevated serum levels of N(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema. Diabetologia 47 (2004) 1376-1379
4. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 813-820
5. Chibber R., Molinatti P.A., and Kohner E.M. Intracellular protein glycation in cultured retinal capillary pericytes and endothelial cells exposed to high-glucose concentration. Cellular and Molecular Biology (Noisy-le-grand) 45 (1999) 47-57
6. Deepa M., Pradeepa R., Rema M., Mohan A., Deepa R., Shanthirani S., et al. The Chennai Urban Rural Epidemiology Study (CURES)-Study design and methodology (urban component) (CURES-I). Journal of the Association of Physicians of India 51 (2003) 863-870
7. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 329 (1993) 977-986
8. Dolhofer-Bliesener R., Lechner B., and Gerbitz K.D. Possible significance of advanced glycation end products in serum in endstage renal disease and in late complications of diabetes. European Journal of clinical Chemistry and Clinical Biochemistry 34 (1996) 355-361
9. Early Treatment of Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic colour fundus photographs-An extension of the modified Airlie House classification (ETDRS Report Number 10). Ophthalmology 98 (1991) 786-806
10. Fosmark D.S., Torjesen P.A., Kilhovd B.K., Berg T.J., Sandvik L., Hanssen K.F., et al. Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. Metabolism 55 (2006) 232-236
11. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 18 (1972) 499-502
12. Genuth S., Sun W., Cleary P., Sell D.R., Dahms W., Malone J., et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications participants with type 1 diabetes. Diabetes 54 (2005) 3103-3111
13. Hammes H.P., Brownlee M., Lin J., Schleicher E., and Bretzel R.G. Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product N-(carboxymethy)lysine independently of glycohaemoglobin concentrations. Diabetologia 42 (1999) 603-607
14. Hanley J.A., and McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143 (1982) 29-36
15. Horie K., Miyata T., Maeda K., Miyata S., Sugiyama S., Sakai H., van Ypersole de Strihou C., Wonnier V.M., and Kurokawa J.L. Immunohistochemical colocalization of glycooxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. Journal of Clinical Investigation 100 (1997) 2995-3004
16. ε-carboxy-methyl]lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 35 (1996) 8075-8083
17. Koga K., Yamagishi S., Okamoto T., Inagaki Y., Amano S., Takeuchi M., and Makita Z. Serum levels of glucose-derived advanced glycation end products are associated with the severity of diabetic retinopathy in type 2 diabetic patients without renal dysfunction. International Journal of Clinical Pharmacology Research 22 (2002) 13-17
18. Monnier V.M., and Cerami A. Nonenzymatic browning in vivo: Possible process for aging of long-lived proteins. Science 211 (1981) 491-493
19. Moss S.E., Meuer S.M., Klein R., Hubbard L.D., Brothers R.J., and Klein B.E. Are seven standard photographic fields necessary for classification of diabetic retinopathy?. Investigative Ophthalmology and Visual Science 30 (1989) 823-828
20. Munch G., Keis R., Wessels A., Riederer P., Bahner U., Heidland A., Niwa T., Lemke H.D., and Schinzel R. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. European Journal of Clinical Chemistry and Clinical Biochemistry 35 (1997) 669-677
21. Ono Y., Aoki S., Ohnishi K., Yasuda T., Kawano K., and Tsukada Y. Increased serum levels of advanced glycation end-products and diabetic complications. Diabetes Research and Clinical Practice 41 (1998) 131-137
22. Porta M., and Bandello F. Diabetic retinopathy. A clinical update. Diabetologia 45 (2002) 1617-1634
23. Rema M., Premkumar S., Anitha B., Deepa R., Pradeepa R., and Mohan V. Prevalence of diabetic retinopathy in urban India: The Chennai Urban Rural Epidemiology Study (CURES) Eye Study I. Investigative Ophthalmology and Visual Science 46 (2005) 2328-2333
24. Sampathkumar R., Balasubramanyam M., Rema M., Premanand C., and Mohan V. A novel advanced glycation index and its association with diabetes and microangiopathy. Metabolism 5 (2005) 1002-1007
25. Sato E., Mori F., Igarashi S., Abiko T., Takeda M., Ishiko S., and Yoshida A. Corneal advanced glycation end products increase in patients with proliferative diabetic retinopathy. Diabetes Care 24 (2001) 479-482
26. Singh R., Barden A., Mori T., and Beilin L. Advanced glycation end-products: A review. Diabetologia 44 (2001) 129-146
27. Soulis T., Thallas V., Youssef S., Gilbert R.E., McWilliam B.G., Murray-McIntosh R.P., and Cooper M.E. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 40 (1997) 619-662
28. Stitt A.W., and Curtis T.M. Advanced glycation and retinal pathology during diabetes. Pharmacological Reports 57 Suppl (2005) 156-168
29. Sugiyama S., Miyata T., Ueda Y., Tanaka H., Maeda K., Kawashima S., Van Ypersele de Strihou C., and Kurokawa K. Plasma levels of pentosidine in diabetic patients: An advanced glycation end product. Journal of the American Society of Nephrology 9 (1998) 1681-1688
30. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
31. Wagner Z., Wittmann I., Mazak I., Schinzel R., Heidland A., Kientsch-Engel R., and Nagy J. N(epsilon)-(carboxymethyl)lysine levels in patients with type 2 diabetes: Role of renal function. American Journal of Kidney Diseases 38 (2001) 785-791
32. Yamaguchi M., Nakamura N., Nakano K., Kitagawa Y., Shigeta H., Hasegawa G., Ienaga K., Nakamura K., Nakazawa Y., Fukui I., Obayashi H., and Kondo M. Immunochemical quantification of crossline as a fluorescent advanced glycation endproduct in erythrocyte membrane proteins from diabetic patients with or without retinopathy. Diabetic Medicine 15 (1998) 458-462
33. Yanagisawa K., Makita Z., Shiroshita K., Ueda T., Fusegawa T., Kuwajima S., et al. Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients. Metabolism 47 (1998) 1348-1353